Analysis of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction for tyrosinase and MART-1 after mononuclear cell collection with cell preparation tubes: a comparison with the whole blood guanidinium isothiocyanate RNA isolation method.
Melanoma cell detection in peripheral blood by tyrosinase reverse transcription-polymerase chain reaction (RT-PCR) is usually performed on RNA isolated from whole blood using a guanidinium isothiocyanate (GITC)/phenol extraction method or from Ficoll Hypaque isolated mononuclear cells. The first method contains environmentally harmful reagents, and the second is laborious in the preanalytical steps. Cell preparation tubes (CPTs) are ready-to-use Ficoll Hypaque-based tubes that avoid the time-consuming and critical loading on Ficoll Hypaque. We examined whether CPTs can be used to determine melanoma cell dissemination in peripheral blood. We first investigated whether melanoma cells were retained in the mononuclear cell layer. All six morphologically different melanoma cell lines studied in the spiking experiments were retained in the upper layer. In further experiments, we were able to detect low dilutions of added SK-MEL-28 cells more consistently after nested RT-PCR for tyrosinase or MART-1 in the RNA isolated from mononuclear cells from CPTs than from RNA isolated with the GITC method. In addition, RNA was extracted from paired blood samples from 24 analysable stage III and stage IV melanoma patients and analysed for the presence of tyrosinase and MART-1 RNA using both the CPT/RNeasy and the whole blood/GITC method. The quality of the CPT/RNeasy RNA was better than the RNA isolated from whole blood with GITC/phenol. However, the RT-PCR results were less unequivocal: MART-1 mRNA was more often detected with CPTIRNeasy compared with whole blood/GITC (six versus three), whereas tyrosinase mRNA was found less often in CPT/RNeasy RNA (two versus eight). Taken together these results suggest that the CPT isolation method is suitable for the isolation of mononuclear cells, including melanoma cells.
de Vries
T J
TJ
Department of Pathology, University Hospital, Nijmegen, The Netherlands. t.j.devries@amc.uva.nl
Fourkour
A
A
Punt
C J
CJ
Ruiter
D J
DJ
van Muijen
G N
GN
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor / Q000097:blood*; D002853:Chromatography, Liquid; D003973:Diatrizoate; D005362:Ficoll; D006146:Guanidines; D006801:Humans; D058965:MART-1 Antigen; D008544:Melanocytes / Q000201:enzymology; D008545:Melanoma / Q000097:blood* / Q000201:enzymology; D014442:Monophenol Monooxygenase / Q000097:blood*; D009363:Neoplasm Proteins / Q000097:blood*; D009360:Neoplastic Cells, Circulating; D014411:Neoplastic Stem Cells / Q000201:enzymology; D012333:RNA, Messenger / Q000097:blood*; D012334:RNA, Neoplasm / Q000097:blood*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D013861:Thiocyanates; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D006146:Guanidines; D058965:MART-1 Antigen; C548667:MLANA protein, human; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D013861:Thiocyanates; D003973:Diatrizoate; D005362:Ficoll; C054436:guanidine thiocyanate; D014442:Monophenol Monooxygenase